Contraceptive Technology Update – December 1, 2024

Abortion Access and Pregnancy Dangers Continue

This issue will look at some of the repercussions of the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization and hear from providers and researchers on what can be done to mitigate the damage to their patients’ health and lives.

How the Dobbs Decision Has Changed Abortion Access and Care in the United States

This article reviews some of the chief reproductive healthcare challenges that have occurred since the U.S. Supreme Court’s decision to overturn Roe v. Wade with the June 2022 decision in Dobbs v. Jackson Women’s Health Organization.

State Shield Law Led to More People Accessing Medication Abortion

State Shield Laws, which protect providers and patients from criminal and civil investigations initiated in abortion-ban states, are successfully improving access to medication abortion, new research shows.

Care of Cancer Patients and People with Chronic Illnesses in Jeopardy Since Dobbs

The U.S. Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization to allow states to ban abortion care has a broader impact than many physicians initially assumed. It can create barriers to women receiving many different types of medical care, including treatment for cancer.

Study Suggests Some EC Clients Interested in Implants When They Have Access

Family planning clinics often have patients who ask for EC, and this is a prime opportunity to talk with them about their ongoing contraceptive needs.

Routine, Opt-Out Screening for Syphilis in Emergency Departments Succeeds

The current healthcare crisis of increases in cases of congenital syphilis suggest reproductive health providers and the public health community need better strategies for identifying people with syphilis infection and getting them into treatment.

Doxy-PEP Could Be Prevention Strategy for Some Patients

Post-exposure prophylaxis (PEP) of doxycycline is recommended by the Centers for Disease Control and Prevention (CDC) for prevention of chlamydia, syphilis, and gonorrhea infections for men who have sex with men (MSM) and transgender women who have had a bacterial sexually transmitted infection (STI) within the past year, according to a new paper on doxycycline-PEP. But it also is a strategy that may work well for cisgender women who have a similar risk profile.